Skip to main content

Advertisement

SpringerLink
Log in

Mid-Regional Proadrenomedullin Levels in Primary Immunodeficiencies Complicated with Pulmonary Manifestations

  • Original Research Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

The development of lower respiratory complications in children with primary immunodeficiencies characterized by recurrent infections significantly contributes to morbidity and mortality. This is clinically more important and specific in the evaluation of prognosis. The inflammatory response that develops throughout the clinical process can cause the release of several biomarkers. This study aimed to evaluate the inflammatory biomarker “mid-regional pro-adrenomedullin (MR-proADM)” levels by distribution of lower respiratory tract complications. Plasma MR-proADM levels were measured in children with (n = 52) and without (n = 103) lower respiratory tract complications. The complicated group was also evaluated as “infective and non-infective” groups. The median MR-proADM levels were higher in the complicated cases (p = 0.175). It was 205.5 (73.4- 562.6) ng/L in the infective group while it was 96.1 (26.1–43.3) ng/L in the non-infective group and the difference between the two groups was statistically significant (p = 0.003). The predictive value of MR-proADM (AUC = 0.749, p = 0.003) was statistically significant compared to CRP (AUC = 0.330, p = 0.040) and SAA (AUC = 0.261, p = 0.004) in the infective group. This study evidences that the MR-proADM levels are higher in PID cases with infective pulmonary complications. Among other markers, MR-proADM appears to be a particularly good predictive inflammation marker for these children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tangye SG, Al-Herz W, Bousfiha A, Chatila T, Cunningham-Rundles C, Etzioni A, et al. Human inborn errors of immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2020;40(1):24–64.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Boushifa AA, Jeddane L, Ailal F, Benhsaien I, Mahlaoui N, Casanova JL, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013;33(1):1–7.

    Article  Google Scholar 

  3. Turvey SE, Bonilla FA, Junker AK. Primary immunodeficiency disease: a practical guide for clinicians. Postgrad Med J. 2009;85(1010):660–6.

    Article  CAS  PubMed  Google Scholar 

  4. Owayed A, Al-Herz W. Sinopulmonary complications in subjects with primary immunodeficiency. Respir Care. 2016;61(8):1067–72.

    Article  PubMed  Google Scholar 

  5. Yazdani R, Abolhassani H, Asgardoon M, Shaghaghi M, Modaresi M, Azizi G, et al. Infectious and noninfectious pulmonary complications in patients with primary immunodeficiency disorders. J Invest Allergol Clin Immunol. 2017;27(4):231–224.

    Article  Google Scholar 

  6. Duru S. Pnomoni ve Biyobelirteçler Guncel Gogus Hastalıkları Serisi. 2014;2(1):78–85.

    Google Scholar 

  7. Corr M, Thomas Waterfield T, Fairley D, McKenna J, Shields MD. A protocol for a systematic review and meta-analysis of the diagnostic accuracy of mid-regional pro-adrenomedullin in predicting invasive bacterial infection in children. BMC. 2020;9(1):69.

    Google Scholar 

  8. Matsui E, Kitamura K, Yoshida M, Kato J, Asada Y, Sumiyoshi A, et al. Biosynthesis and secretion of adrenomedullin and proadrenomedullin N-terminal 20 peptide in a rat model of endotoxin shock. Hypertens Res. 2001;24(5):543–9.

    Article  CAS  PubMed  Google Scholar 

  9. Sole-Ribalta S, Bobillo-Perez S, Valls A, Girona-Alarcon M, Launes C, Cambra FJ, et al. Diagnostic and prognostic value of procalcitonin and mid-regional pro-adrenomedullin in septic paediatric patients. Eur J Pediatr. 2020;179(7):1089–96.

    Article  CAS  PubMed  Google Scholar 

  10. Christ-Crain M, Muller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Resp J. 2007;30(3):556–73.

    Article  CAS  Google Scholar 

  11. Principi N, Esposito S. Biomarkers in pediatric community-acquired pneumonia. Int J Mol Sci. 2017;18(2):447.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Angeletti S, Dicuonzo G, Fioravanti M, De Cesaris M, Fogolari M, Lo Presti A, et al. Procalcitonin, MR-proadrenomedullin, and cytokines measurement in sepsis diagnosis: advantages from test combination. Dis Markers. 2015;2015(10):951532.

    PubMed  PubMed Central  Google Scholar 

  13. Viaggi B, Poole D, Tujjar O, Marchiani S, Ognibene A, Finazzi S. Mid-regional pro-adrenomedullin for the prediction of organ failure in infection. Results from a single centre study. PLoS ONE. 2018;13(8):e0201491.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Schuetz P, Marlowe Rt J, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): a qualitative clinical review. Clin Chem Lab Med. 2015;53(4):521–39.

    Article  CAS  PubMed  Google Scholar 

  15. Decker SO, Sigl A, Grumaz C, Stevens P, Vainshtein Y, Zimmermann S, et al. Immune-response patterns and next generation sequencing diagnostics for the detection of mycoses in patients with septic shock-results of a combined clinical and experimental investigation. Int J Mol Sci. 2017;18(8):1796.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Klip IT, Voors AA, Anker SD, Hillege HL, Struck J, Squire L, et al. Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction. Heart. 2011;97(11):892–8.

    Article  CAS  PubMed  Google Scholar 

  17. Wild PS, Schnabel RB, Lubos E, Zeller T, Sinning CR, Keller T, et al. Midregional proadrenomedullin for prediction of cardiovascular events in coronary artery disease: results from the AtheroGene study. Clin Chem. 2011;58(1):226–36.

    Article  PubMed  Google Scholar 

  18. Benito J, Luaces-Cubells C, Mintegi S, Astobiza E, Martinez-Indart L, Valls-Lafont A, et al. Lack of value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 for prediction of severe bacterial infections in infants with fever without a source. Eur J Pediatr. 2013;172(11):1441–9.

    Article  CAS  PubMed  Google Scholar 

  19. Oncel MY, Dilmen U, Erdeve O, Ozdemir R, Calisici E, Yurttutan S, et al. Proadrenomedullin as a prognostic marker in neonatal sepsis. Pediatr Res. 2012;72(5):507–12.

    Article  CAS  PubMed  Google Scholar 

  20. Aghamohammadi A, Bahrami A, Mamishi S, Mohammadi B, Abolhassani H, Parvaneh N, et al. Impact of delayed diagnosis in children with primary antibody deficiencies. J Microbiol Immunol Infect. 2011;44(3):229–34.

    Article  PubMed  Google Scholar 

  21. Membrila-Mondragon J, Staines-Boone AT, Sanchez-Sanchez LM, Ruiz-Pedraza MD. Pulmonary complications in pediatric patients with primary immunodeficiency. Gac Med Mex. 2015;151(2):145–51.

    Google Scholar 

  22. Jesenak M, Banovcin P, Jesenakova B, Babusikova E. Pulmonary manifestations of primary immunodeficiency. Front Pediatr. 2014;2:77.

    Article  PubMed  PubMed Central  Google Scholar 

  23. McCusker C, Warrington R. Primary immunodeficiency. Allergy Asthma Clin Immunol. 2011;7(S1):11.

    Article  Google Scholar 

  24. Kilic SS, Ozel M, Hafizoglu D, Karaca NE, Aksu G, Kutukculer N. The prevalences and patient characteristics of primary immunodeficiency diseases in Turkey-two centers study. J Clin Immunol. 2013;33(1):74–83.

    Article  CAS  PubMed  Google Scholar 

  25. Nonas S. Pulmonary manifestations of primary immunodeficiency disorders. Immunol Allergy Clin. 2015;35(4):753–66.

    Google Scholar 

  26. Wood P, Stanworth S, Burton J, Jones A, Peckham DG, Green T, et al. Primary Immunodeficiency Network. Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clin Exp Immunol. 2007;149(3):410–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Mahdaviani SA, Darougar S, Mansouri D, Tashayoıe-Nejad S, Movahed M, Aghdam KR, et al. Pulmonary complications of predominantly antibody immunodeficiencies in a tertiary lung center. Interv Med Appl Sci. 2019;11(1):1–7.

    PubMed  Google Scholar 

  28. Bierry G, Boileau J, Barnig C, Gasser B, Korganow AS, Buy X, et al. Thoracic manifestations of primary humoral immunodeficiency: a comprehensive review. Radiographics. 2009;29(7):1909–20.

    Article  PubMed  Google Scholar 

  29. Patrawala M, Cui Y, Peng L, Fuleihan RL, Garabedian EK, Patel K, et al. Pulmonary disease burden in primary immune deficiency disorders: Data from USIDNET Registry. J Clin Immunol. 2020;40(2):340–9.

    Article  CAS  PubMed  Google Scholar 

  30. Jaye DL, Waites KB. Clinical applications of C-reactive protein in pediatrics. Pediatr Infect Dis J. 1997;16(8):735–47.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang Y, Zhang J, Sheng H, Li H, Wang R. Acute phase reactant serum amyloid A in inflammation and other diseases. Adv Clin Chem. 2019;90:25–80.

    Article  CAS  PubMed  Google Scholar 

  32. Andres C, Andaluz-Ojeda D, Cicuendez R, Nogales L, Martin S, Martin-Fernandez M, et al. MR- proADM to detect specific types of organ failure in infection. Eur J Clin Invest. 2020;50(6):e13246.

    Article  CAS  PubMed  Google Scholar 

  33. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia. Crit Care. 2006;10(3):R96.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9(6):R816-24.

    Article  PubMed  Google Scholar 

  35. Citgez E, Zuur-Telgen M, van der Palen J, van der Valk P, Stolz D, Brusse-Keizer M. Stable-State Midrange proadrenomedullin is associated with severe exacerbations in COPD. Chest. 2018;154(1):51–7.

    Article  PubMed  Google Scholar 

  36. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, et al. Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care. 2010;14(3):R106.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kruger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T, et al. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med. 2010;182(11):1426–34.

    Article  PubMed  Google Scholar 

  38. Sanchez MS, Hernandez JC, Hernandez-Bou S, Teruel GC, Rodriguez JV, Cubells CL. Pro-adrenomedullin usefulness in the management of children with community acquired pneumonia, a preliminar prospective observational study. BMC Res. 2012;5(1):363.

    Google Scholar 

  39. Alcoba G, Manzano S, Lacroix L, Galetto-Lacour A, Gervaix A. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study. BMC Infect Dis. 2015;15(1):347.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Bueno Campana M, Ruperez Lucas M, Fernandez Rincon A, Calvo C, Moran Roldan L. de la Morena Martinez R. Mid-regional pro-adrenomedullin could be a biomarker of severity in bronchiolitis. Acta Paediatr. 2018;107(8):1467–8.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank to Ege University Scientific Research Projects Coordination Unit (Career Start Support Project Number: TKB-2019-20570).

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Ege University Faculty of Medicine, 35040, Bornova- Izmir, Turkey

    Elif Azarsiz

  2. Department of Pediatric Immunology, Ege University Faculty of Medicine, Izmir, Turkey

    Neslihan Karaca & Necil Kutukculer

Authors
  1. Elif Azarsiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neslihan Karaca
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Necil Kutukculer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EA and NK contributed to study design and data collection. EA performed the statistical analyses and writing the first draft of article. NK and NK performed clinical evaluation. EA, NK, and NK all participated in critical revision of the article for important intellectual content and final approval of the version to be published.

Corresponding author

Correspondence to Elif Azarsiz.

Ethics declarations

Author Disclosure Statement

No competing financial interests exist.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azarsiz, E., Karaca, N. & Kutukculer, N. Mid-Regional Proadrenomedullin Levels in Primary Immunodeficiencies Complicated with Pulmonary Manifestations. Ind J Clin Biochem 38, 475–484 (2023). https://doi.org/10.1007/s12291-022-01061-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-022-01061-9

Keywords

Search

Navigation